CA1148865A - Compose pour le traitement des affections vasculaires - Google Patents

Compose pour le traitement des affections vasculaires

Info

Publication number: CA1148865A
Authority: CA; Canada
Prior art keywords: treatment; disease; patient; potassium permanganate; vascular disease
Prior art date: 1979-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000320547A

Other languages

English (en)

Inventor

Ernesto Lince Lalinde (Deceased)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LINCE ISAZA JESUS E

Original Assignee

LINCE ISAZA JESUS E

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-01-30

Filing date

1979-01-30

Publication date

1983-06-28

1979-01-30 Application filed by LINCE ISAZA JESUS E filed Critical LINCE ISAZA JESUS E

1979-01-30 Priority to CA000320547A priority Critical patent/CA1148865A/fr

1983-06-28 Application granted granted Critical

1983-06-28 Publication of CA1148865A publication Critical patent/CA1148865A/fr

Status Expired legal-status Critical Current

Links

208000019553 vascular disease Diseases 0.000 title claims abstract description 17
239000000203 mixture Substances 0.000 title claims abstract description 11
239000012286 potassium permanganate Substances 0.000 claims abstract description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
201000010099 disease Diseases 0.000 claims abstract description 15
238000010255 intramuscular injection Methods 0.000 claims abstract description 10
239000007927 intramuscular injection Substances 0.000 claims abstract description 10
230000001225 therapeutic effect Effects 0.000 claims abstract description 6
239000000243 solution Substances 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 2
229960001841 potassium permanganate Drugs 0.000 abstract description 23
239000007864 aqueous solution Substances 0.000 abstract description 11
238000000034 method Methods 0.000 abstract description 10
210000002683 foot Anatomy 0.000 description 12
208000002193 Pain Diseases 0.000 description 11
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
201000001320 Atherosclerosis Diseases 0.000 description 6
206010017711 Gangrene Diseases 0.000 description 6
210000003414 extremity Anatomy 0.000 description 6
210000002414 leg Anatomy 0.000 description 6
206010043540 Thromboangiitis obliterans Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000003589 local anesthetic agent Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
206010046996 Varicose vein Diseases 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
208000027185 varicose disease Diseases 0.000 description 4
206010033546 Pallor Diseases 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000002792 vascular Effects 0.000 description 3
208000031104 Arterial Occlusive disease Diseases 0.000 description 2
206010003178 Arterial thrombosis Diseases 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
206010069729 Collateral circulation Diseases 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
206010022562 Intermittent claudication Diseases 0.000 description 2
208000035901 Ischaemic ulcer Diseases 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
208000000558 Varicose Ulcer Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000002266 amputation Methods 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
229940035674 anesthetics Drugs 0.000 description 2
208000021328 arterial occlusion Diseases 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
206010003230 arteritis Diseases 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
235000021074 carbohydrate intake Nutrition 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000003137 popliteal artery Anatomy 0.000 description 2
229960003975 potassium Drugs 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
235000007686 potassium Nutrition 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
235000021076 total caloric intake Nutrition 0.000 description 2
229940072358 xylocaine Drugs 0.000 description 2
241000173529 Aconitum napellus Species 0.000 description 1
235000019737 Animal fat Nutrition 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010062542 Arterial insufficiency Diseases 0.000 description 1
201000008283 Atrophic Rhinitis Diseases 0.000 description 1
208000033386 Buerger disease Diseases 0.000 description 1
101100423891 Caenorhabditis elegans qars-1 gene Proteins 0.000 description 1
208000004434 Calcinosis Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
208000001034 Frostbite Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000008277 Immersion Foot Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
206010039088 Rhinitis atrophic Diseases 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
206010044584 Trench foot Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229940023019 aconite Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
208000028922 artery disease Diseases 0.000 description 1
235000019606 astringent taste Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000002308 calcification Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
208000024980 claudication Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002638 denervation Effects 0.000 description 1
230000001877 deodorizing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000013156 embolectomy Methods 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000012476 oxidizable substance Substances 0.000 description 1
VJKUPQSHOVKBCO-ZTYBEOBUSA-N picrotoxin Chemical compound O=C([C@@]12OC1C[C@]1(O)[C@@]32C)O[C@@H]3C2[C@@H](C(=C)C)C1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3C2[C@@H](C(C)(O)C)C1C(=O)O2 VJKUPQSHOVKBCO-ZTYBEOBUSA-N 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
235000019505 tobacco product Nutrition 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000320547A 1979-01-30 1979-01-30 Compose pour le traitement des affections vasculaires Expired CA1148865A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000320547A CA1148865A (fr)	1979-01-30	1979-01-30	Compose pour le traitement des affections vasculaires

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000320547A CA1148865A (fr)	1979-01-30	1979-01-30	Compose pour le traitement des affections vasculaires

Publications (1)

Publication Number	Publication Date
CA1148865A true CA1148865A (fr)	1983-06-28

Family

ID=4113424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000320547A Expired CA1148865A (fr)	1979-01-30	1979-01-30	Compose pour le traitement des affections vasculaires

Country Status (1)

Country	Link
CA (1)	CA1148865A (fr)

1979
- 1979-01-30 CA CA000320547A patent/CA1148865A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-06-28	MKEX	Expiry

Publication	Publication Date	Title
Miller et al.	1998	Staged skin and subcutaneous excision for lymphedema: a favorable report of long-term results
Mills Sr	2003	Buerger’s disease in the 21st century: diagnosis, clinical features, and therapy
Holmlund et al.	1978	Treatment of ureteral colic with intravenous indomethacin
Smith et al.	1996	Intravenous naftidrofuryl for critical limb ischaemia
Mashiah et al.	1995	Phenol lumbar sympathetic block in diabetic lower limb ischemia
Miyazaki et al.	2005	Long-term results of treatments for varicose veins due to greater saphenous vein insufficiency
JPH0399019A (ja)	1991-04-24	毛細血管脆弱の処置の局所的使用のための製薬学的組成物
Verbov	1980	Cutaneous polyarteritis nodosa in a young child.
Collens et al.	1936	The use of intermittent venous compression in the treatment of peripheral vascular disease: A preliminary report
Dean et al.	2002	Successful pharmacologic treatment of lower extremity ulcerations in 5 patients with chronic critical limb ischemia.
US4150119A (en)	1979-04-17	Method for treatment of vascular disease
CA1148865A (fr)	1983-06-28	Compose pour le traitement des affections vasculaires
US3463854A (en)	1969-08-26	Method of treatment for effecting vasodilation of the small arteries in human beings
JP2813624B2 (ja)	1998-10-22	循環不全治療用医薬組成物
Allen	1942	Thrombo-angiitis obliterans
Murayama et al.	1991	Entrapment of the saphenous nerve by branches of the femoral vessels. A report of two cases.
EP1372629A2 (fr)	2004-01-02	Traitement therapeutique
AU2002220960A1 (en)	2002-08-22	Regeneration of blood vessels
WESSLER et al.	1953	Studies in Peripheral Arterial Occlusive Disease: II. Clinical Findings in Patients with Advanced Arterial Obstruction and Gangrene
EP0142597A2 (fr)	1985-05-29	Utilisation d'un mélange de composants pour la fabrication d'une composition utilisée dans le traitement de la maladie de Buerger
Pardy et al.	1983	Prostaglandin therapy in severe limb ischemia
Heinzen et al.	1954	Thrombosis of the Abdominal Aorta and Iliac Arteries
Shaw	1960	Neonatal sciatic palsy from injection into the umbilical cord
Pretty	1929	Varicose Veins and Their Treatment by Sclerosis
Burt	1954	Anticoagulants